Skip to main content

Remifentanil Pharmacokinetics and Pharmacodynamics

A Preliminary Appraisal

Clinical Pharmacokinetics volume 29, pages 80–94 (1995)Cite this article

Summary

Remifentanil is a novel, short-acting μ-receptor opioid agonist currently in the late stages of development. A member of the 4-anilidopiperidine class, it is unique among the currently marketed agents because of its ester structure. Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h). Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.

Because of its unique metabolic pathway (among this group of drugs) and rapid clearance, remifentanil represents a new pharmacokinetic class of opioid. Unlike the other fentanyl congeners, termination of the therapeutic effect of remifentanil mostly depends on metabolic clearance rather than on redistribution. The context-sensitive half-time [defined as the time necessary to achieve a 50% decrease in blood (or plasma) concentration after termination of a variable-length, continuous infusion targeted to maintain a steady-state concentration, where the ‘context’ is the duration of the infusion] is strikingly short for remifentanil, and this is perhaps the most compelling evidence of the pharmacokinetic singularity of the drug. Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.

Pharmacodynamically, remifentanil is similar to the other fentanyl congeners. The drug produces physiological changes consistent with potent γ-receptor agonist activity, including analgesia and sedation. Its adverse effect profile (like that of the other drugs of this class) includes ventilatory depression, nausea, vomiting, muscular rigidity, bradycardia and pruritus. Because it does not release histamine upon injection, remifentanil has fewer haemodynamic adverse effects than morphine. The therapeutic potency of remifentanil is somewhat less than that of fentanyl, with an effective concentration (producing 50% of maximal effect, as measured by electroencephalography) of approximately 15 to 20 µg/L. Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2 ke0(a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.

Remifentanil is likely to be a welcome addition to the anaesthesia drug formulary. Anaesthetists have long recognised the need for a short-acting opioid with a predictable pharmacokinetic profile. Because the length of surgical procedures is often unpredictable, and because the level of surgical stimulation against which the depth of anaesthesia must be balanced is highly variable and dynamic, the advantages of predictably short-acting agents are obvious.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Feldman PL, James MK, Brackeen MF, et al. Design, synthesis, and pharmacological evaluation of ultrashort to long acting opioid analgetics. J Med Chem 1991; 34: 2202–8

    PubMed  Article  CAS  Google Scholar 

  2. Data on file, Glaxo, Research Triangle Park, NC, USA

  3. Grosse CM, Davis IM, Arrendal RF, et al. Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard. J Pharm Biomed Anal 1994; 12(2): 195–203

    PubMed  Article  CAS  Google Scholar 

  4. Selinger K, Lanzo C, Sekut A. Determination of remifentanil in human and dog blood by HPLC with UV detection. J Pharm Biomed Anal 1994; 12(2): 243–8

    PubMed  Article  CAS  Google Scholar 

  5. Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short acting opioid: remifentanil (GI87084B). Anesth Analg 1993; 77: 1031–40

    PubMed  Article  CAS  Google Scholar 

  6. Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881–92

    PubMed  Article  CAS  Google Scholar 

  7. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993; 79: 893–903

    PubMed  Article  CAS  Google Scholar 

  8. Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics and pharmacodynamics of GI87084B [abstract]. Anesthesiology 1992; 77: A369

    Article  Google Scholar 

  9. Egan TD, Minto C, Lemmens HJM, et al. Remifentanil versus alfentanil: comparative pharmacokinetics [abstract]. Anesthesiology 1994; 81: A373

    Article  Google Scholar 

  10. Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci 1972; 61: 536–41

    PubMed  Article  CAS  Google Scholar 

  11. Beal SL, Sheiner LB. NONMEM User’s Guide. San Francisco: University of California at San Francisco, 1979

    Google Scholar 

  12. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159–66

    PubMed  CAS  Google Scholar 

  13. Rosow C. Remifentanil: a unique opioid analgesic [editorial]. Anesthesiology 1993; 79: 875–6

    PubMed  CAS  Google Scholar 

  14. Dershwitz M, Rosow CE, Michalowski P, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease compared with normal subjects [abstract]. Anesthesiology 1994; 81: A377

    Article  Google Scholar 

  15. Hoke J, Muir K, Glass P, et al. Pharmacokinetics of remifentanil and its metabolite (GI90291) in subjects with renal disease [abstract]. Clin Pharmacol Ther 1995; 57: PI55

    Google Scholar 

  16. Shlugman D, Dufore S, Dershwitz M, et al. Respiratory effects of remifentanil in subjects with severe renal impairment compared to matched controls [abstract]. Anesthesiology 1994; 81: A1417

    Article  Google Scholar 

  17. Gupta S, Haigh A, Kenny G, et al. The pharmacokinetics of remifentanil injection during hypothermic cardiopulmonary bypass in humans. Proceedings of the 16th Annual Meeting of the Society of Cardiovascular Anesthesiologists; 1994 Apr 23–27: Montreal, Canada

  18. Egan TD, Gambus P, Billard V, et al. Gender has no effect on the pharmacokinetics or pharmacodynamics of remifentanil [abstract]. Anesthesiology. In press

  19. Hughes MA, Glass PSA, Jacobs JR. Context-sensitive halftimes in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1991; 76: 334–41

    Article  Google Scholar 

  20. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics and rational opioid selection. Anesthesiology 1991; 74:53–63

    PubMed  Article  CAS  Google Scholar 

  21. Kapila A, Muir KT, Hermann DJ, et al. Measured context sensitive half-times of remifentanil and alfentanil [abstract]. Anesthesiology 1993; 79: A377

    Google Scholar 

  22. James MK, Feldman PL, Schuster SV, et al. Opioid receptor activity of GI87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther 1991; 259(2): 712–8

    PubMed  CAS  Google Scholar 

  23. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone reversal of depressed ventilatory response to hypoxia during continuous infusion of remifentanil [abstract]. Anesthesiology 1993; 79: A1203

    Google Scholar 

  24. Hoffman WE, Cunningham F, James MK, et al. Effects of remifentanil, a new short-acting opioid, on cerebral blood flow, brain electrical activity, and intracranial pressure in dogs anesthetized with isoflurane and nitrous oxide. Anesthesiology 1993; 79: 107–13

    PubMed  Article  CAS  Google Scholar 

  25. Cunningham FE, Hoffman WE, Baughman VL. Comparative pharmacodynamics of remifentanil, a new short acting opioid, GI90921A the active metabolite and alfentanil [abstract]. Anesthesiology 1993; 79: A712

    Google Scholar 

  26. Egan TD, Minto C, Lemmens HJM, et al. Remifentanil versus alfentanil: comparative pharmacodynamics [abstract]. Anesthesiology 1994; 81: A374

    Article  Google Scholar 

  27. Salmenpera M, Wilson D, Szlam F, et al. Anesthetic potency of the opioid GI87084B in dogs [abstract]. Anesthesiology 1992; 77: A368

    Article  Google Scholar 

  28. Kapila A, Lang E, Glass P, et al. MAC reduction of isoflurane by remifentanil [abstract]. Anesthesiology 1994; 81: A378

    Article  Google Scholar 

  29. Randel GI, Fragen RJ, Librojo ES, et al. Remifentanil blood concentration effect relationship at intubation and skin incision in surgical patients compared to alfentanil [abstract]. Anesthesiology 1994; 81: A375

    Article  Google Scholar 

  30. James MK, Vuong A, Grizzle MK, et al. Hemodynamic effects of GI 87084B, an ultra-short acting mu-opioid analgesic, in anesthetized dogs. J Pharmacol Exp Ther 1992; 263(1): 84–91

    PubMed  CAS  Google Scholar 

  31. Pitts MC, Palmore MM, Salmenpera MT, et al. Pilot study: hemodynamic effects of intravenous GI87084B in patients undergoing elective surgery [abstract]. Anesthesiology 1992; 77: A101

    Article  Google Scholar 

  32. Reitan JA, Stengert KB, Wymore ML, et al. Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. Anesth Analg 1978; 57: 31–6

    PubMed  CAS  Google Scholar 

  33. Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses release after remifentanil. Anesth Analg 1995; 80: 990–3

    PubMed  CAS  Google Scholar 

  34. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56: 93–6

    PubMed  Article  CAS  Google Scholar 

  35. Joshi P, Jhaveri R, Bauman V, et al. Comparative trial of remifentanil and alfentanil for anesthesia induction [abstract]. Anesthesiology 1993; 79: A379

    Google Scholar 

  36. Streisand JB, Bailey PL, Lemaire L, et al. Fentanyl-induced rigidity and unconsciousness in human volunteers. Anesthesiology 1993; 78: 629–34

    PubMed  Article  CAS  Google Scholar 

  37. Mather LE. Pharmacokinetic and pharmacodynamic profiles of opioid analgesics: a sameness amongst equals? [editorial]. Pain 1990; 43: 3–6

    PubMed  Article  CAS  Google Scholar 

  38. Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. Anesthesiology 1992; 76: 327–30

    PubMed  Article  CAS  Google Scholar 

  39. Kallar SK, Hurt TW, Wetchler BV, et al. A single blind, comparative study of the safety and efficacy of remifentanil and alfentanil for outpatient anesthesia [abstract]. Anesthesiology 1994; 81: A32

    Article  Google Scholar 

  40. Fragen RJ, Randel GI, Librojo ES, et al. The interaction of remifentanil and propofol to prevent response to tracheal intubation and the start of surgery for outpatient knee arthroscopy [abstract]. Anesthesiology 1994; 81: A376

    Article  Google Scholar 

  41. Johnstone RE, Jozefczyk KG. Costs of anesthetic drugs: experiences with a cost education trial. Anesth Analg 1994; 78: 766–71

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Anesthesiology, University Health Sciences Center, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, Utah, 84132, USA

    Talmage D. Egan

Authors
  1. Talmage D. Egan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Egan, T.D. Remifentanil Pharmacokinetics and Pharmacodynamics. Clin. Pharmacokinet. 29, 80–94 (1995). https://doi.org/10.2165/00003088-199529020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199529020-00003

Keywords

  • Fentanyl
  • Adis International Limited
  • Remifentanil
  • Sufentanil
  • Alfentanil